文献速递肺外科

临床T1aN0M0典型类癌的切除范围与淋巴结评估

Extent of Resection and Lymph Node Assessment for Clinical Stage T1aN0M0 Typical Carcinoid Tumors.
PubMed 文献 · Ann Thorac Surg · 2017-11-11

基于美国国家癌症数据库1998-2012年1495例临床T1aN0M0典型类癌患者,比较肺叶切除与亚肺叶切除及淋巴结评估对总生存的影响。结果显示亚肺叶切除与肺叶切除总生存相似,但淋巴结评估可识别淋巴结升级,后者是死亡的最强独立预测因素。

要点

  • 亚肺叶切除与肺叶切除的总生存相似,5年总生存率分别为87%与88%(p=0.3)。
  • 24.5%的患者未行淋巴结评估,淋巴结升级患者5年生存率仅65%。
  • 淋巴结升级是总死亡的最强独立预测因素,应常规进行淋巴结评估。

核心结论

  • 对于临床T1aN0M0典型类癌,亚肺叶切除与肺叶切除的总生存相似。
  • 无论切除类型如何,淋巴结评估均重要,可识别淋巴结升级,后者是总死亡的最强独立预测因素。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库1998-2012年数据。
  • 纳入1495例接受肺叶切除或亚肺叶切除的临床T1aN0M0肺实质内典型类癌患者。
  • 采用Kaplan-Meier法分析总生存,多变量Cox比例风险模型确定独立死亡预测因素。

主要发现

  • 536例(35.9%)接受亚肺叶切除(楔形切除429例,肺段切除91例),959例(64.2%)接受肺叶切除。
  • 366例(24.5%)未行淋巴结评估。
  • 5年总生存率为87%;肺叶切除为88%,亚肺叶切除为87%(p=0.3)。
  • 淋巴结升级患者5年总生存率为65%,无淋巴结升级者为89%,未行淋巴结评估者为86%(p=0.002)。

临床怎么用

  • 对于临床T1aN0M0典型类癌,可考虑亚肺叶切除以保留肺功能,但需进行淋巴结评估。
  • 应常规采样或清扫淋巴结以识别淋巴结升级,指导预后判断和后续治疗。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 未报告亚肺叶切除与肺叶切除在淋巴结评估率上的差异。
  • 未提供多变量分析中淋巴结升级的风险比及置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal extent of lung resection and lymph node (LN) assessment for surgical treatment of clinical stage T1aN0M0 typical carcinoid tumors is unclear. Using a cohort including only these patients, we aimed to determine the impact of extent of lung resection and LN assessment on overall survival. METHODS: Patients undergoing lobectomy or sublobar resection for clinical stage T1aN0M0 intraparenchymal typical carcinoid tumor were identified in the National Cancer Data Base from 1998 to 2012. Kaplan-Meier analysis was used to determine overall survival. A multivariable Cox proportional hazards model was used to determine independent predictors of mortality. RESULTS: Of 1,495 patients, 536 (35.9%) had sublobar resection (wedge resection, n = 429; segmentectomy, n = 91) and 959 (64.2%) had lobectomy. There were 366 patients (24.5%) with no LN assessment. As tumor size increased, sublobar resection decreased and LN assessment increased. Overall, 60 patients (4.0%) were upstaged. Fifty-two patients were upstaged because of LN metastases (40 pN1, 11 pN2, and 1 pN3). The 5-year overall survival rate was 87%. It was 88% for lobectomy versus 87% for sublobar resection (p = 0.3), 65% for LN upstaging versus 89% for patients without LN upstaging, and 86% for patients with no LN assessment (p = 0.002). Independent predictors of mortality included LN upstaging, age, male sex, and Charlson comorbidity index. CONCLUSIONS: For patients with clinical stage T1aN0M0 typical carcinoid, sublobar resection results in similar overall survival compared with lobectomy. However, regardless of resection type, LN assessment is important to identify LN upstaging, the strongest independent predictor of overall mortality.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Brown LM, Cooke DT, Jett JR, et al. Extent of Resection and Lymph Node Assessment for Clinical Stage T1aN0M0 Typical Carcinoid Tumors. Ann Thorac Surg. 2017. PMID: 29132704. doi:10.1016/j.athoracsur.2017.07.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。